Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. Co.'s CF-focused pipeline consists of CFTR modulators including correctors, potentiators and amplifiers. Upon discovery of amplifiers, a class of CFTR modulators, Co. utilized their mechanism of action as a drug screening tool and identified correctors and potentiators that Co. is developing as combination therapies. The YMTX stock yearly return is shown above.
The yearly return on the YMTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the YMTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|